We describe a case report where buprenorphine was successfully used for the management of kratom (Mitragyna speciosa) dependency during the Covid-19 pandemic in a specialist community substance misuse treatment service. The individual had a notable iatrogenic dependency on oral over the counter and prescribed opioid medication. She resorted to using kratom as a ‘tea’ to self-detoxify before getting into difficulty. Upon presentation, she disclosed using kratom up to 70 g/day with hourly dosing, in addition to co-codamol (8 mg codeine/500 mg paracetamol tablets) three times a week. Initiation of oral buprenorphine sublingual tablets was complicated due to Covid-19: dispensing arrangements were liberalised from the outset and the dose was incrementally increased, eventually to 24 mg/day. Comorbidities included mental health conditions and chronic pain which improved with buprenorphine treatment and psychotherapy. Further research is required to determine optimal regimens for the management of kratom dependency. This case study adds to the current paucity of published data regarding how to manage such cases in the community setting, which is important since kratom is thought to be increasingly used in the western world.
AbbottKLFlanneryPCGillKS, et al. (2020)
Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews52(1): 44–65.
2.
AbdullahHMAHaqILamfersR (2019a)
Cardiac arrest in a young healthy male patient secondary to kratom ingestion: Is this ‘legal high’ substance more dangerous than initially thought?BMJ Case Reports12(7): e229778.
3.
AbdullahM (2020)
Kratom dependence and treatment options: A comprehensive review of the literature. Current Drug Targets21: 1566.
4.
AbdullahMSinghDNarayananS, et al. (2019b)
Socio-demographic characteristics, kratom use and quality of life (QoL) of regular kratom (Mitragyna speciosa korth.) users. Malaysian Journal of Medicine and Health Sciences15(3): 4–9.
5.
AdkinsJEBoyerEWMcCurdyCR (2011)
Mitragyna speciosa, a psychoactive tree from southeast Asia with opioid activity. Current Topics in Medicinal Chemistry11(9): 1165–1175.
6.
AfzalHEsangMRahmanS (2020)
A case of kratom-induced seizures. Cureus12(1): e6588.
7.
AgapoffJRKilaruU (2019)
Outpatient buprenorphine induction and maintenance treatment for kratom dependence: A case study. Journal of Substance Use24(6): 575–577.
8.
AggarwalGRobertsonEMcKinlayJ, et al. (2018)
Death from kratom toxicity and the possible role of intralipid. Journal of the Intensive Care Society19(1): 61–63.
9.
BathRBucholzTBurosAF, et al. (2020)
Self-reported health diagnoses and demographic correlates with kratom use: Results from an online survey. Journal of Addiction Medicine14(3): 244–252.
10.
BoweAKerrPL (2020)
A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: Effects of buprenorphine in clinical management. Journal of Psychoactive Drugs52(5): 447–452.
11.
BoyerEWBabuKMAdkinsJE, et al. (2008)
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction103: 1048–1050.
12.
BoyerEWBabuKMMacalinoGE, et al. (2007)
Self-treatment of opioid withdrawal with a dietary supplement, kratom. American Journal on Addictions16(5): 352–356.
13.
BureshM (2018)
Treatment of kratom dependence with buprenorphine-naloxone maintenance. Journal of Addiction Medicine12(6): 481–483.
14.
CoeMAPillitteriJLSembowerMA, et al. (2019)
Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence202: 24–32.
DiepJChinDTGuptaS, et al. (2018)
Kratom, an emerging drug of abuse: A case report of overdose and management of withdrawal. A&A Practice10(8): 192–194.
17.
EastlackSCCornettEMKayeAD (2020)
Kratom-pharmacology, clinical implications, and outlook: A comprehensive review. Pain and Therapy9(1): 55–69.
18.
GagnierJJKienleGAltmanDG, et al.; the CARE Group (2013)
The CARE guidelines: Consensus-based clinical case reporting guideline development. BMJ Case Reports2013(Oct23 1): bcr2013201554.
19.
Galbis-ReigD (2016)
A case report of kratom addiction and withdrawal. WMJ115(1): 49–52.
20.
GrundmannO (2017)
Patterns of kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence176: 63–70.
KhazaeliAJerryJMVazirianM (2018)
Treatment of kratom withdrawal and addiction with buprenorphine. Journal of Addiction Medicine12(6): 493–495.
23.
MatsonMSchenkN (2019)
Fatality of 33-year-old man involving kratom toxicity. Journal of Forensic Sciences64(6): 1933–1935.
24.
McCauleyJLMercerMABarthKS, et al. (2014)
Pain management perceptions among prescription opioid dependent individuals. Drug and Alcohol Dependence142: 354–358.
25.
McWhirterLMorrisS (2010)
A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. European Addiction Research16(4): 229–231.
26.
National Institute for Health and Care Excellence (NICE) (2007) Methadone and buprenorphine for the management of opioid dependence. Technology appraisal guidance (TA114). Available at: https://nice.org.uk/guidance/ta114 (accessed 13 December 2020).
27.
ObachRSCoxLMTremaineLM (2005)
Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metabolism and Disposition33(2): 262–270.
OverbeekDLAbrahamJMunzerBW (2019)
Kratom (mitragynine) ingestion requiring naloxone reversal. Clinical Practice and Cases in Emergency Medicine3(1): 24–26.
30.
ProzialeckWCEdwardsJRLamarPC, et al. (2020)
Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the Western suburbs of Chicago. International Journal of Environmental Research and Public Health17(15): 5512.
SchmuhlKKGardnerSMCottrillCB, et al. (2020)
Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult. Substance Abuse41(3): 311–314.
34.
ShelegSVCollinsGB (2011)
A coincidence of addiction to ‘‘kratom’’ and severe primary hypothyroidism. Journal of Addiction Medicine5: 300–301.
35.
SinghDMüllerCPVicknasingamBK (2014)
Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence139: 132–137.
36.
StanciuCNGnanasegaramSAAhmedS, et al. (2019)
Kratom withdrawal: A systematic review with case series. Journal of Psychoactive Drugs51(1): 12–18.
37.
SwoggerMTWalshMT (2018)
Kratom use and mental health: A systematic review. Drug and Alcohol Dependence183: 134–140.
38.
Taylor SAnnandFBurkinshawP, et al. (2019) Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review.
London, UK:
Public Health England.
39.
WessonDRLingW (2003)
The clinical opiate withdrawal scale (COWS). Journal of Psychoactive Drugs35(2): 253–259.
40.
Wiss DA and Waterhous TS (2014) Nutrition Therapy for Eating Disorders, Substance Use Disorders, and Addictions. In: Brewerton T., Baker Dennis A. (eds) Eating Disorders, Addictions and Substance Use Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45378-6_23
